Pulmonary Biomedical Services and Patient Delivery Platform signed a definitive agreement to acquire MedoveX Corp. (OTCPK:MDVX) in a reverse merger transaction on October 15, 2018. As consideration, MedoveX Corp. will issue 0.58 million shares of common stock, 0.30 million shares of Series C Preferred Stock will convert into 1,000 shares of Common Stock and shall represent the right to convert into 55% of the outstanding common stock, $0.35 million in cash and will assume liabilities. MedoveX Corp. will pay $0.3 million as the termination fee. Medovex shall maintain a minimum cash balance of $1.65 million on its balance sheet at the time of closing. As on October 15, 2018, Jarrett Gorlin, James R. Lawson, Randal R. Betz, John C. Thomas, Jr., James R. Andrews, Clyde A. Hennies, Jon Mogford, Scott Haufe and Jesse W. Crowne, gave their resignations to Larry W. Papasan, Co-Chairman of the Board. Larry W. Papasan invited newly appointed President and Chief Executive Officer, William E. Horne, to join the Board as Chairman. Larry W. Papasan tendered his resignation to William E. Horne, leaving William E. Horne as the sole director of MedoveX Corp. The transaction is subject to customary closing conditions, including amendment to certificate of incorporation, target board resigns, approval by regulatory board and execution of ancillary agreements. Sharon McBrayer Johnson of Womble Bond Dickinson acted as legal advisor to MedoveX Corp.